Imagen de Portada

Xenium and IMC data in "Spatial Single-Cell Profiling Identifies Immune-Cold Tumor Niches Linked to Early Progression on EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant NSCLC"

Fuente: Zenodo

Guardado en:

Detalles Bibliográficos
Autores principales:	Li, Haochen, Lownik, Joseph, Reckamp, Karen, Merchant, Akil
Formato:	Recurso digital
Publicado:	Zenodo 2026
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC
por: Fengwu Lin, et al.
Publicado: (2025)

Spatial Heterogeneity of PD‐L1 Expression as a Biomarker for Third‐Generation EGFR‐TKI Response in Advanced EGFR‐Mutant NSCLC
por: Yidan Zhang, et al.
Publicado: (2025)

Decoding Brain Metastasis With Liquid Biopsy: Biomarkers and Technologies in EGFR ‐Mutant NSCLC
por: Yuxiang Sun, et al.
Publicado: (2026)

Persist or resist: Immune checkpoint inhibitors in EGFR‐mutated NSCLC
por: Pengcheng Zhu, et al.
Publicado: (2024)

DFT and Molecular Docking Studies of N‐(7‐Indazolyl)benzenesulfonamides as Potential Drugs Targeting EGFR‐Tyrosine Kinase Inhibitors
por: Aziz Moumad, et al.
Publicado: (2025)

Real‐World Survival Outcomes in EGFR‐Mutant Advanced NSCLC Treated With EGFR TKIs: Insights From a Single‐Center Clinical Data Warehouse Analysis in South Korea
por: Bomi Kim, et al.
Publicado: (2025)

First‐Line Third‐Generation EGFR Tyrosine Kinase Inhibitor Monotherapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer: A Systematic Review and Network Meta‐Analysis
por: Wei Du, et al.
Publicado: (2025)

Magnoliae flos Overcomes EGFR ‐ TKI Resistance in NSCLC by Enhancing EGFR Ubiquitination
por: Qing Wu, et al.
Publicado: (2026)

Structural Analysis of the Macrocyclic Inhibitor BI‐4020 Binding to EGFR Kinase
por: Tyler S. Beyett, et al.
Publicado: (2024)

Overcoming EGFR‐Mediated Dendritic Cell Dysfunction to Enhance Anti‐tumor Immunity in EGFR‐Mutant NSCLC by Precisely Targeting CD73 With pH‐responsive Nanocarriers
por: Xiaoling Shang, et al.
Publicado: (2025)

Sacituzumab tirumotecan improved survival for patients with EGFR TKI–resistant, EGFR‐mutant advanced NSCLC
por: Leah Lawrence
Publicado: (2026)

Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell‐Derived Cardiomyocytes and FDA Adverse Events Reporting System
por: Shota Yanagida, et al.
Publicado: (2025)

More treatment options emerge for EGFR ‐mutant NSCLC
por: Leah Lawrence
Publicado: (2026)

VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR‐Tyrosine Kinase Inhibitor‐Resistant Non‐Small Cell Lung Cancer
por: Sehwa Hong, et al.
Publicado: (2025)

Periostin Safeguards EGFR‐Driven Genomic Instability and Sustains the Immune‐Suppressive Niche in Glioblastoma
por: Hongjun Liu, et al.
Publicado: (2026)

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Zanubrutinib in Immune Thrombocytopenia
por: Qiu‐Sha Huang, et al.
Publicado: (2025)

Design, Synthesis, and Molecular Profiling of Pyrimidine‐Furan Derivatives Targeting EGFR WT , EGFR T790M , and EGFR L858R/T790M/C797S in NSCLC: In Vitro and In Silico Evaluation
por: Rohit Pal, et al.
Publicado: (2025)

Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer
por: Zhen Chen, et al.
Publicado: (2024)

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms
por: Xin Liao, et al.
Publicado: (2024)

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
por: Jin Tian, et al.
Publicado: (2024)

chuvalab/Xenium_IMC_OVA: spatial omics analysis pipeline
por: fuweilumc
Publicado: (2025)

Overcoming Resistance in EGFR‐Mutant Cancers: A Comprehensive Review of Inhibitor Evolution and SAR‐Based Design
por: Hemlata Naykwadi, et al.
Publicado: (2026)

Clinical Outcomes of Later‐Generation EGFR ‐ TKIs for Uncommon EGFR Mutations in NSCLC : A Multicenter Real‐World Study
por: Lisa Shigematsu, et al.
Publicado: (2025)

Pericytes Modulate Third‐Generation Tyrosine Kinase Inhibitor Sensitivity in EGFR‐Mutated Lung Cancer Cells Through IL32‐β5‐Integrin Paracrine Signaling
por: Cheng Huang, et al.
Publicado: (2024)

The Efficacy of Immune Checkpoint Inhibitors in the EGFR Mutant and Wild‐Type Non‐Small Cell Lung Cancer Is Positively Associated With the Maturation and Abundance of Dendritic Cells
por: Fengqi Xiao, et al.
Publicado: (2025)

Recent Progress of Molecular Design and Activities of Spleen Tyrosine Kinase (SYK) Inhibitors
por: Jiayi Shen, et al.
Publicado: (2025)

Thoracic radiotherapy synergizes with first‐line EGFR ‐ TKIs in advanced EGFR ‐mutant NSCLC : A dual‐center real‐world study
por: Zhuoying Tian, et al.
Publicado: (2025)

Rational Design of Triazole Hydrazide Derivatives With Imidazo[2,1‐ b ]thiazole Scaffolds as Targeted EGFR Inhibitors in NSCLC
por: Mohamed K. Elgohary, et al.
Publicado: (2025)

GCMS and LCMS data of exometabolome of parental and Osimertinib-resistant EGFR-mutant NSCLC
por: Bramanti, Emilia
Publicado: (2025)

EGFR exon 20–targeting sunvozertinib granted accelerated approval for advanced NSCLC
por: Leah Lawrence
Publicado: (2025)

Baseline and changes in inflammatory parameters for patients with EGFR‐mutated NSCLC treated with afatinib
por: Zi‐Ting Chang, et al.
Publicado: (2025)

Improved progression‐free survival, increased toxicities seen with amivantamab for EGFR‐mutant NSCLC
por: Mary Beth Nierengarten
Publicado: (2024)

Assessing EGFR‐mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy
por: Wei‐Chun Chen, et al.
Publicado: (2024)

Possible new mechanisms of primary drug resistance in NSCLC with EGFR mutation treated with Osimertinib
por: Lujing Shao, et al.
Publicado: (2025)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
por: Shang‐Gin Wu, et al.
Publicado: (2024)

Efficacy and Safety of EGF / EGFR Vaccines in EGFR ‐Driven Solid Tumors: A Systematic Review and Meta‐Analysis of Controlled and Single‐Arm Studies
por: Fei Chen, et al.
Publicado: (2025)

The Adverse Impact of Tyrosine Kinase Inhibitors on Wound Healing and Repair
por: William J. Nahm, et al.
Publicado: (2025)

Conformational Dynamics of Wild‐Type to Triple Mutant EGFR‐TKD Captured by Coarse‐Grained Simulations
por: Showkat Ahmad Mir, et al.
Publicado: (2025)

Bruton's Tyrosine Kinase: Pathophysiological Roles and Inhibitor‐Based Therapeutic Advances
por: Simhadri Goud Gundrathi, et al.
Publicado: (2026)

DRD1 suppresses cell proliferation and reduces EGFR activation and PD‐L1 expression in NSCLC
por: Christopher E. Grant, et al.
Publicado: (2024)